KUALA LUMPUR: Sunzen Biotech Bhd expects to return to profitability this year, thanks to strong demand for its small and medium-sized enterprise (SME) loan financing.
Director Ching Chee Pun said the company was optimistic about increasing profits for its traditional Chinese medicine, herbal health foods and beverages, and bird’s nest under its EcoLite brand, all part of its human health care segment.
“Sunzen has already made profits in the last two quarters, owing primarily to EcoLite and the successful acquisition of Finsource Credit. We’ve seen an increase in demand for loan financing from SMEs as a result of the Covid-19 pandemic.
“We hope to make even more progress in the final two quarters of our current fiscal year. We hope to turn things around this year, otherwise, we are confident that we will be able to return to profitability in 2023,” he told the New Straits Times.
